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Background: The N1 definition of 2010 UICC/AJCC staging system for nasopharyngeal carcinoma (NPC) covers
quite a large range of nodal pattern. The objective of this research is to investigate prognostic value of lymph
nodes related factors including involvement of both cervical lymph nodes (CLNs) and retropharyngeal lymph nodes
(RLNs) or not, size and number of cervical lymph nodes (CLNs) in N1 patients with NPC.
Methods: 142 newly diagnosed non-metastatic N1 patients with NPC, staged according to the 2010 AJCC staging
system for NPC were retrospectively enrolled. All patients had undergone contrast-enhanced magnetic resonance
imaging (MRI), and received radiotherapy, with or without chemotherapy as their primary treatment.
Results: The median follow-up was 48 months. The 5-year local recurrence-free survival (LFS), nodal recurrence-free
survival (NFS), local-regional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), progression-free
survival (PFS), and overall survival (OS) of the whole group were 82.3%, 83.0%, 81.0%, 82.1%, 75.3% and 89.8%,
respectively. In univariate analysis, patients with both CLNs and RLNs involvement showed a significant lower
DMFS, PFS and LRFS than the rest patients (p = 0.004 p = 0.003 and p = 0.034, respectively). Neither size nor number
of CLNs affected the survival. In multivariate analysis, involvement of both CLNs and RLNs was an independent
prognostic factor for DMFS and PFS (p = 0.019, p = 0.019), but there was no enough evidence confirming its
prognostic value for LRFS (p = 0.051).
Conclusions: For N1 patients with NPC, involvement of both RLNs and CLNs may be a potentially prognostic factor
for distant metastasis and disease progression. The N stage for N1 patients with involvement of both cervical lymph
nodes and retropharyngeal lymph nodes might need to be deliberated.
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Nasopharyngeal carcinoma (NPC) is one of the most
endemic head and neck cancer in Southeast Asia and
East Asia. The incidence of NPC in Southern China is
approximately 30 to 80 per 100,000 people per year [1].
Radiotherapy is the common recognized treatment mo-
dality for nasopharyngeal carcinoma. The use of IMRT* Correspondence: hucsu62@yahoo.com
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reproduction in any medium, provided the orand the combination with chemotherapy have improved
the locoregional control of NPC, while distant metastasis
and recurrence are the main failures after treatment [2,3].
Tumor-nodal-metastasis (TNM) system for nasopharyn-
geal carcinoma (NPC) is helpful in predicting prognosis,
facilitating treatment planning, and exchanging infor-
mation between different centers. Generally speaking,
the T-classification can predict local control, while the
N-classification can predict neck and distant control.
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for NPC is the most common recognized staging system.
The most recently published seventh edition of the
UICC/AJCC staging system have recommended sev-
eral changes in the definition of T-classification and
N-classification to the sixth edition, and one of the im-
portant improvement was upgrading patients with in-
volvement of retropharyngeal lymph nodes (RLNs)
only and without cervical lymph node (CLN) metas-
tasis to N1 [4,5].
According to the 7th edition UICC/AJCC staging system,
N1 classification for NPC is defined as following: unilat-
eral lymph nodes, 6 cm or less, above the supraclavicular
fossa, and/or retropharyngeal lymph nodes, 6 cm or
less (unilateral or bilateral) [5]. Thus, the N1 definition
of UICC/AJCC staging system covers quite a large
range of nodal patterns, which may includes patients
with or without retropharyngeal lymph nodes, patients
with or without cervical lymph nodes, patients with
cervical lymph nodes of different sizes, and patients
with single or multiple cervical lymph nodes. It is rea-
sonable to hypothesize that N1 patients with different
nodal characteristics may have different prognosis.
Few studies had ever focused on the possibly different
outcomes in NPC patients with N1 disease. This study
was conducted to find out whether long-term prognosis
differs among N1 patients with different nodal characteris-
tics, in order to suggest whether detailed classification
or improvement is needed in the definition of N1 in 7th
edition UICC/AJCC staging system for NPC, and to
more effectively guide future treatment.
Methods
Patients
From November 2007 through November 2009, 180
consecutive patients were enrolled in this study and were
retrospectively reviewed. The inclusion criteria were as
following: (1) biopsy-proven nasopharyngeal carcinoma;
(2) no previous treatment including chemotherapy, radio-
therapy, surgery, etc.; (3) with pretreatment magnetic
resonance imaging (MRI) of the nasopharynx and neck;
(4) N1 classification according to the definition of the
7th edition UICC/AJCC staging system for NPC, which
dominantly depends on MRI; (5) from 18 to 70 years old;
(6) receiving radiotherapy in our institute. The exclusion
criteria were as follows: (1) with distant metastasis proven
by clinical or radiologic evidence; (2) previously diagnosed
as other head and neck cancers and had received surgery,
radiotherapy, or chemotherapy before.
This study was approved by the Research Ethics Com-
mittee of Fudan University Shanghai Cancer Hospital
and was performed in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki and
all subsequent revisions.Pretreatment evaluation
Pretreatment evaluation were composed of complete med-
ical history, physical examination, indirect or fiberoptic
endoscopic examination of nasopharynx, biopsy of the
neoplasm in nasopharynx, MRI scans of nasopharynx and
neck, chest CT or X-ray, abdominal sonography, and bone
scans for T3-T4 and symptomatic patients.
All patients were staged according to the 7th edition
of AJCC staging system [5]. Cervical lymph nodes were
defined as metastatic if the shortest axial diameter of
jugulodigastric lymph node was ≥11 mm, or the shortest
axial diameter of other lymph nodes was ≥10 mm, or there
was a group of three or more lymph nodes in critical size
[6,7]. The lateral RLNs were considered metastatic with
their shortest diameter ≥5 mm. Any visible node in the
median retropharyngeal group was considered malignant
[8,9]. Moreover, the presence of extracapsular spread and
central necrosis were also signs of metastasis [6–9].
Radiotherapy
Intensity-Modulated Radiation Therapy (IMRT)
Patients were immobilized in the supine position with a
thermoplastic mask. CT simulation was performed after
immobilization, obtaining 3-mm slices from the anterior
clinoid process to the hyoid bone, and 5-mm slices from
the hyoid bone to 2 cm below the sternoclavicular joint.
The gross tumor volume (GTV) included primary tumor
and enlarged RLNs. The clinical target volume (CTV)
included bilateral coverage of levels II, III, VA and RLNs.
The CTV should also cover the entire nasopharynx,
parapharyngeal space, clivus, base of skull, pterygoid
fossa, posterior half of ethmoidal sinus, inferior sphenoid
sinus, and posterior third of nasal cavity and maxillary
sinuses. A margin of 3–5 mm around GTV and CTV
should be added to account for the patient motion and
set-up error. The total dose to primary tumor was 66 Gy in
30 fractions for T1 or T2 disease, 70.4 Gy in 32 fractions
for T3 or T4 lesion. A total dose of 60 Gy was delivered to
the CTV in 30–32 fractions.
Conventional two-dimensional radiotherapy (2D-RT)
For patients treated with 2D-RT, immobilization was the
same as that used for IMRT. Two lateral opposed fields
were used to irradiate the nasopharynx and upper neck,
followed by the shrinking-field technique to limit dose
to spinal cord. A Boost of 4–6 Gy was routinely delivered
to the skull base in patients with involvement of skull base
or intracranial extension. An anterior field was used to
treat the neck. In patients with no cervical lymph node
metastasis, only the upper neck was treated, including
levels II, III and VA. In others the whole neck received
radiation, including levels II, III, IV, V, according to the
EORTC and RTOG consensus guideline. The accumulated
dose to the primary tumor was 70–76 Gy with 2 Gy per
Table 1 Patient characteristics
Number Percentile (%)




Chemotherapy Yes 126 88.7
No 16 11.3
Radiotherapy 2D-RT 35 24.6
3D-CRT/IMRT 107 75.4
T Stage T1-2 85 59.9
T3-4 57 40.1
RLN RLN+ 109 76.8
RLN- 33 23.2
CLN CLN+ 110 77.5
CLN- 32 22.5
RLN indicates retropharyngeal lymph node.
CLN indicates cervical lymph node.
Table 2 Patterns of failure
Failure Frequency %
Local recurrence 9 6.3
Nodal recurrence 8 5.6
Local & nodal recurrence 5 3.5
Distant metastasis 15 10.6
Local recurrence & distant metastasis 1 0.7
Local & nodal recurrence & distant metastasis 1 0.7
Death 12 8.5
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50–62 Gy with 1.8 to 2 Gy per fraction.
Boost
Residual disease diagnosed by clinical examination or
MRI was boosted. Superficial lesion was treated by
brachytherapy, with a dose of 6–16 Gy in one or two
weekly fractions. More advanced disease was treated by
small field external-beam radiotherapy, including IMRT,
3D-RT, 2D-RT and stereotactic radio-surgery. The boost
dose was 6–8 Gy.
Chemotherapy
There were several regimens of neoadjuvant chemotherapy
and adjuvant chemotherapy in our institution, including
PF, TPF and GP. The TPF protocol consisted of docetaxel
75 mg/m2 IV on day 1, cisplatin75 mg/m2 IV on day 1,
and 5-fu 500 mg/m2 d continuously IV on day1–5. The
PF protocol consisted of cisplatin 75 mg/m2 IV on day 1
and 5-fu 500 mg/m2 d continuously IV on day 1–5. The
GP regimen included cisplatin 75 mg/m2d IV on day 1
and gemcitabine 1000 mg/m2 IV on day 1, 8. Regimens
were repeated every 3 weeks for 2 cycles as neoadjuvant
chemotherapy. This was followed by cisplatin 40 mg/m2
IV weekly during radiation. For patients who received
adjuvant chemotherapy, regimens were repeated every
3–4 week for 3 cycles.
Follow-up
The follow-up period ranged from the first day of the
date of initiation of treatment until death or the last
visit. The median follow-up period was 48 months
(range, 2 – 66 months).
Patients were followed every 3 months in the first to
second year, then every 6 months in the third to fifth
year and once a year thereafter. In each visit, medical
history, physical examination and nasopharyngoscopy
were performed. Nasopharyngeal MRI was performed 3
months and 1 year after completion of radiotherapy, and
every 6 months in the second to fifth year, and then
yearly thereafter. The following tests were done at least
every year: chest CT or X-ray, abdominal sonography,
and bone scan when clinically indicated. Late toxicities
were evaluated according to the toxicity criteria of the
RTOG [10].
Statistical analysis
All analyses were performed using the SPSS software,
version 19.0. The actuarial rates were estimated by the
Kaplan–Meier method, and the survival curves were
compared with the log-rank test [11]. The following
endpoints were assessed: overall survival (OS), local
recurrence-free survival (LFS), nodal recurrence-free
survival (NFS), local-regional recurrence-free survival(LRFS), distant metastasis-free survival (DMFS), and
progression-free survival (PFS). All the endpoints were
defined as the interval from the date of initiation of
treatment to the date of the failure or death, or last
follow-up. Multivariate analyses with the Cox proportional
hazards model [12] were used to test for independent
significance by backward elimination of insignificant
explanatory variables of the different parameters.
Results and discussion
Patients and treatments
Between 2007 and 2009, a total of 180 NPC patients with
N1 disease were enrolled in this study. Among them, 1
patient failed to complete radiotherapy due to Grade 3
mucositis and poor general condition. The pretreatment
nasopharyngeal MR images of 37 patients were not avail-
able because of image-preserving reason. Thus, there were
142 assessable patients. Clinical characteristics were listed
in Table 1. The median age was 50 years old (range: 23–70
years). Of patients with stage III/IV disease, 98.2% (56/57)
received chemotherapy. Of patients with stage II disease,




CLN + & RLN+ 77
Longest diameter of CLN ≤ 3 cm 65
3 cm < Longest diameter of CLN ≤ 6 cm 45
Single CLN metastasis 49
Multiple CLNs metastases 61
CLN in lower neck 6
Unilateral RLNs metastasis 80
Bilateral RLNs metastasis 29
RLN indicates retropharyngeal lymph node.
CLN indicates cervical lymph node.
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treated by 2D-RT, and the rest 107 patients were treated
by IMRT. 85 patients belonged to T1-T2 stage, and 57
belonged to T3-T4 stage.
Survival and patterns of failure
With a median follow-up of 48 months (range, 2 – 66
months), a total of 9 local recurrences, 8 nodal recur-
rences, 15 distant metastasis, and 12 death were observed.
The main failure was distant metastasis. Among the 15
patients developing distant metastasis, 14 had both
cervical lymph nodes and retropharyngeal lymph nodes
involvement, and the rest one had only retropharyngeal
lymph node metastasis. The patterns of failure were listed
in Table 2, and the common sites of distant failure were
liver, lung and bone. The 5-year local recurrence-free
survival (LFS), nodal recurrence-free survival (NFS),
local-regional recurrence-free survival (LRFS), distant
metastasis-free survival (DMFS), progression-free survivalFigure 1 DMFS, PFS and LRFS of patients with different nodal charact
than those with either CLNs or RLNs ( p=0.004). (B) Patients with both CLN
(p=0.003). (C) Patients with both CLNs and RLNs showed lower LRFS than(PFS), and overall survival (OS) of the whole group
were 82.3%, 83.0%, 81.0%, 82.1%, 75.3% and 89.8%,
respectively.
Patterns of lymph nodes involvement
ALL of the 142 NPC patients were assured to be classified
into N1 category according to the 7th edition UICC/AJCC
staging system. The patterns of metastatic lymph nodes
involvement were presented in Table 3. Among the popu-
lation, 110 patients had metastatic cervical lymph nodes
(CLNs), and the rest 32 patients had no cervical lymph
nodes but with unilateral or bilateral retropharyngeal
lymph nodes (RLNs). 77 patients had both RLNs and
CLNs involvement, and the 33 patients had CLNs only.
The longest diameters of CLNs in 65 patients were less
than 3 centimeters. 61 patients had more than 1 CLNs,
and the rest 49 patients had only single CLN. Only 6
patients had CLNs in level IV, while the CLNs of other
patients were all in level Ib, II, and III. Among the 109
patients had metastatic RLNs, 80 were with unilateral RLN
metastasis, and 29 were with bilateral RLN metastasis.
Univariate and multivariate analyses
The Kaplan-Meier method was used to estimate LFS,
NFS, LRFS, DMFS, PFS, and OS for different nodal status,
including patients with both CLNs and RLNs versus the
rest, longest diameter of CLN 3-6 cm versus ≤ 3 cm, and
single CLN versus multiple CLN.
Among the 142 patients, 32 patients with only RLNs
(no CLN) and 33 patients with only CLNs (no RLN)
showed similar prognosis in LFS, NFS, LRFS, DMFS, PFS
and OS (96.4% vs 75.5%, p = 0.181; 96.4% vs 75.8%, p =
0.166; 96.4% vs 75.8%, p = 0.166; 96.7% vs 93.8%, p = 0.636;
96.7% vs 75.8%, p = 0.177; 96.4% vs 93.8%, p = 0.630). How-
ever, those with both CLNs and RLNs involvement showed
a significant lower DMFS, PFS and LRFS than those witheristics. (A) Patients with both CLNs and RLNs showed lower DMFS
s and RLNs showed lower PFS than those with either CLNs or RLNs
those with either CLNs or RLNs ( p=0.034).
Table 4 Univariate analysis of lymph nodes related variables and other clinical factors for 5-year survival
Variable Patient no. LFS (%) p NFS (%) p LRFS (%) p DMFS (%) p PFS (%) p OS (%) p
Both CLNs and RLNs
Yes 77 77.2 0.068 78.4 0.112 74.6 0.034 72.5 0.004 65.5 0.003 85.3 0.119
No 65 87.1 87.3 87.3 95.2 87.4 95.1
Size of CLNs
CLN ≤ 3 cm 66 81.0 0.988 83.5 0.940 80.5 0.966 79.8 0.426 74.0 0.448 88.8 0.853
CLN 3-6 cm 44 74.1 74.0 72.2 76.0 64.7 87.2
Number of CLNs
Single CLN 62 73.9 0.328 74.1 0.174 70.7 0.154 71.5 0.240 60.3 0.132 85.6 0.562
Multiple CLNs 48 84.8 86.4 84.8 86.7 81.2 90.5
Age
<50 74 83.8 0.858 84.8 0.683 82.4 0.881 81.3 0.649 77.4 0.802 89.9 0.542
>50 68 81.0 81.3 79.8 83.0 74.0 88.9
Sex
Male 106 79.5 0.215 80.6 0.215 78.9 0.355 77.0 0.066 70.6 0.114 86.9 0.123
Female 36 89.3 89.0 86.3 94.3 86.3 97.1
Radiotherapy
2D-RT 35 77.5 0.263 80.5 0.526 75.2 0.207 66.7 0.009 62.4 0.027 83.0 0.160
IMRT 107 83.2 83.0 82.1 89.5 80.5 92.7
Chemotherapy
Yes 16 92.3 0.379 84.6 0.995 84.6 0.815 85.7 0.937 77.9 0.950 92.3 0.765
No 126 80.7 82.4 80.2 81.5 74.4 89.4
Pathology
WHO II 37 76.2 0.238 75.1 0.167 73.0 0.171 79.3 0.347 68.7 0.183 88.1 0.473
WHO III 105 84.3 85.5 83.5 82.6 76.9 90.4
T Stage
T1-T2 85 89.6 0.032 88.5 0.165 87.3 0.097 87.8 0.005 81.6 0.012 94.7 0.048
T3-T4 57 72.5 75.7 72.6 72.5 65.4 82.4
Bold numbers, indicated there was statistically significant difference (p value < 0.05).
RLN indicates retropharyngeal lymph node.
CLN indicates cervical lymph node.
2D-RT indicates Conventional two-dimensional radiotherapy and IMRT indicates Intensity-Modulated Radiation Therapy.
LFS, NFS, LRFS, DMFS, PFS and OS indicate for local recurrence-free survival, nodal recurrence-free survival, local-regional recurrence-free survival, distant
metastasis-free survival, progression-free survival and overall survival.
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difference was observed in LFS, NFS, and OS between
the two groups (Table 4). As T stage and concurrent
chemotherapy may affect patients’ survival, independent-
samples t-test was conducted to make sure that the
distribution of T stage and that of patients received
concurrent chemotherapy were well balanced between
the two groups (p = 0.727, p = 0.117).
We also performed a subgroup analysis by T stage. In
patients with T3-T4 disease, the significant difference in
DMFS and PFS (90.9% vs 59.5%, p = 0.021; 79.5% vs
54.7%, p = 0.025) between the two groups still existed and
a relatively lower LRFS (79.5% vs 65.9%) was observed in
patients with both metastatic CLNs and RLNs in spite of
no statistical difference. In those with T1-T2 disease, wecould also see an increasing rate of DMFS, PFS and LRFS
in patients with either CLNs or RLNs involvement over
those with both CLNs and RLNs (97.6% vs 82.1%; 95.1%
vs 73.6%; 94.9% vs 80.9%).
Neither the size nor number of CLNs was the factor
affecting the survival of patients. No significant difference
were found in LFS, NFS, LRFS, DMFS, PFS and OS in
patients with CLN ≤ 3 cm vs those with CLN > 3 cm, and in
patients with single CLN vs those with multiple CLN
(Table 4). After stratified by Tclassification, size and number
of CLNs still did not associate with the above endpoints.
In multivariate analysis, involvement of both CLNs and
RLNs or not, T stage, technique of radiotherapy and sex,
which were proved by univariate analysis to have the
potential affecting survival rate were included in the
Shi et al. Radiation Oncology 2014, 9:7 Page 6 of 8
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that involvement of both CLNs and RLNs was an inde-
pendent prognostic factor for DMFS and PFS (p = 0.019,
p = 0.019), but there was no enough evidence confirming
its prognostic value for LRFS (p = 0.051) (Table 5).
Discussion
Our study is the first research focusing on the outcome
and prognosis of NPC patients with N1 disease according
to the 7th edition UICC/AJCC staging system. And the
stages of patients in our study were all based on magnetic
resonance imaging, which is the commonly recognized
best modality for staging locoregional NPC [13–15]
and allows a more accurate assessment of the extent of
primary tumor and lymph node status than computerized
tomography (CT) because of its multiplanar capacity and
improved tissue contrast [14].
The 5-year LFS, NFS, LRFS, DMFS, PFS, and OS were
82.3%, 83.0%, 81.0%, 82.1%, 75.3% and 89.8%, respectively.
The results of our study are comparable to other series
[16–18]. As 24.6% (35/142) of our patients enrolled in
were treated by 2D-RT, the 5-year LFS, DMFS, PFS are
slightly lower than those of Sun et al. treated with 3D-
CRT and IMRT (90%, 86% and 77%, respectively) [16].
The overall survival of 89.8% is remarkably better than
64.4–67.9% of He et al. [17] and Gao et al. [18] treated
with 2D technique.
In our study, no significant difference was observed
in all survival related endpoints between patients with
CLN > 3 cm and those with CLN ≤ 3 cm, and between
patients with single CLN and multiple CLN, indicating
that size and number of metastatic CLNs might not be
the valuable factors which affect N1 patients’ survival.
Quite a large amount of studies have compared different
endpoints between N0 patients (6th edition) with RLNs
and N0 patients (6th edition) without RLN, and between
N0 patients (6th edition) with RLNs and N1 patientsTable 5 Summary of multivariate analysis of factors in patien
Endpoint Factor B
DMFS Both CLNs and RLNs involvement −1.498
T stage −1.374
Technique of radiotherapy 0.978
Sex 1.310
PFS Both CLNs and RLNs involvement −1.179
T stage −1.046
Technique of radiotherapy 0.773
LRFS Both CLNs and RLNs involvement −1.002
T stage −0.671
Bold numbers, indicated there was statistically significant difference (p value < 0.05
RLN indicates retropharyngeal lymph node.
CLN indicates cervical lymph node.
LRFS, DMFS, PFS indicate for local-regional recurrence-free survival, distant metasta(6th edition). The results reported by these studies were
similar: in N0 (6th edition) patients, involvement of RLNs
was an independent predictor for DMFS [19–21]. Ma’s
study showed that RLNs metastases also predict for OS
and LRFS [19]. And all these studies found no significant
difference in hazard ratio for distant metastasis and death
between patients with N0 disease with RLNs involvement
and patients with N1 disease (6th edition) [19–21]. Never-
theless, few studies has focused on the probably prog-
nostic value of metastatic lymph nodes pattern in N1
patients. In our study, of the 15 patients developing
distant metastasis, 14 patients were with both CLNs
and RLNs involvement. And among the 142 patients,
those with either RLNs or CLNs involvement showed a
significantly better DMFS, PFS and LRFS than those
with both CLNs and RLNs patients. Multivariate ana-
lysis confirmed that those with both CLNs and RLNs
metastases had a significantly higher risk for distant
metastasis and disease progression. This result should
be considered reasonable, with historical data nearly all
concluding retropharyngeal lymph node metastasis as a
prognostic factor for DMFS in N0 patients (6th edition).
Anatomically, RLNs are located within the retrophar-
yngeal space. The pharyngeal constrictor muscles bound
this space anteriorly, the pre-vertebral fascia posteriorly,
the carotid sheath laterally, the skull base superiorly and
inferiorly the space continues to the level of vertebra
C3 at its caudal extent [22]. The involvement of RLNs
in nasopharyngeal carcinoma is frequent, with a high
incidence of RLNs metastases ranges from 63.4%-94%
[8,20,23,24] assessed by MRI. Actually, several clinical
studies showed that RLNs represent first-echelon lymph
nodes typically involved in NPC [8,24,25].
The publishing of 2010 AJCC/UICC staging system
(7th edition) have upgraded NPC patients with RLNs
metastases with no other CLN to N1, and before that, the
staging of RLNs was ambiguous. A good staging systemts with N1 disease











sis-free survival and progression-free survival.
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differ among the groups (hazard discrimination); 2) the
subsets defined by the T, N, and M classifications that
comprise a given group should have similar survival rates
(hazard consistency); 3) the patient distribution across the
groups should be balanced; and 4) the cure prediction
should be high (outcome prediction) [26]. The inclusion
of CLN-/RLN + patients into N1 by the 7th AJCC staging
system improved the hazard consistency of N1 patients
and improved hazard discrimination among N subsets
[19,20]. Now the result of our study showed that the in-
volvement of both CLNs and RLNs might also be a
prognostic factor for N1 patients. It is reasonable to
hypothesis that defining patients with both CLNs and
RLNs involvement as a particular subset of N1 (for in-
stance, N1b) might improve the hazard discrimination
of the staging system.
However, there were several limitations of this study.
Since it was a retrospective study, the distribution of
patient number in different groups and subgroups were
not well balanced. The treatment modalities used in pa-
tients including radiation technique and chemotherapy
regimens were not uniform. The total amount of 142
patients analyzed was a relatively small number. Hence,
the current finding could only be taken as preliminary.
A larger sample of uniform treatment is needed for ob-
serving whether differences in the treatment outcomes
exist between N1 patients with both RLNs and CLNs
involvement and the rest N1 patients, and even between
N1 patients with both RLNs and CLNs involvement
and N2 patients, thus to conclude whether changes and
improvement are needed in the definition of N1 stage
of 7th edition AJCC/UICC staging system.
Conclusions
Our study was the first one focusing on the prognosis
of different subsets of NPC patients with N1 disease
(7th edition UICC/AJCC staging system). The 5-year OS
was 89.8% and the main treatment failure pattern was
distant metastasis. The involvement of both cervical
lymph nodes and retropharyngeal lymph nodes may be
a potentially prognostic factor for distant metastasis
and disease progression in N1 patients, which needs a
larger sample to confirm the result. The N stage for
N1 patients with involvement of both cervical lymph
nodes and retropharyngeal lymph nodes may need to
be deliberated.
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